SGLT2is and GLP-1RAs—What Are the Benefits?
In this medfyle
Expert commentary by Alice YY Cheng, MD, FRCPC
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2021 - 81st Scientific Sessions and presented by:
Jason Alexander, MD
University of Chicago
Chicago, IL, USA
The content is produced by Infomedica, the official reporting partner of ADA 2021.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Alice YY Cheng, MD, FRCPC
University of Toronto, Toronto, Canada
About the Expert
Alice YY Cheng, MD, FRCPC
University of Toronto, Toronto, Canada
Dr. Cheng is an Endocrinologist at Trillium Health Partners and Unity Health Toronto and is an Associate Professor at the University of Toronto. She has been involved with the development of the Diabetes Canada clinical practice guidelines since 2003 served as Chair for the 2013 version. Currently, she is the Chair of the Professional Section of Diabetes Canada and an Associate Editor for the Canadian Journal of Diabetes. In recognition of her contribution, she has received the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada. She is also the creator of The Med Ed Pledge – an initiative to increase Diversity & Inclusion in continuing medical education (www.theMedEdPledge.com).
Disclosures:
Advisory board: Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Insulet, HLS Therapeutics, Janssen, Medtronic, Merck, Novartis, Novo Nordisk, Sanofi
Speaking: Abbott, Astra Zeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eisai, Eli Lilly, HLS Therapeutics, Janssen, Medtronic, Merck, Novo Nordisk, SanofiClinical trials: Applied Therapeutics, Sanofi, Boehringer Ingelheim, Eli Lilly
References
1. Zinman B, Wanner C, Lachin M, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22):2117–28.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377(7):644–57.
3. Wiviott SD, Raz I, Bonaca MP, et al.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380(4):347–57.
4. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373(23):2247–57.
5. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375(4):311–22.
6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834–44.
7. Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017;377(13):1228–39.
8. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394(10193):121–30.
9. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(suppl 1):S111–24.
10. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573.
